A combination of encorafenib (a BRAF inhibitor) and cetuximab (an EGFR inhibitor) has been shown in clinical trials to improve survival in patients with metastatic colorectal cancer harboring the BRAF V600E mutation. This evidence concerns the gene EGFR and metastatic colorectal cancer.